What is the effect of SGI-1776 on normal peripheral blood mononuclear cells (PBMCs) compared to MCL cells?
Label:chem
Topic
SGI-1776 is designed to target Pim kinases, which are overexpressed in MCL cells but not in normal PBMCs. This selective targeting is important for minimizing toxicity to healthy cells.
Answer
SGI-1776 treatment does not significantly affect normal PBMCs, unlike MCL cells. In normal PBMCs, SGI-1776 does not consistently reduce the phosphorylation of Pim kinase targets or the levels of short-lived proteins like Mcl-1 and cyclin D1. Additionally, apoptosis is not induced in normal PBMCs after SGI-1776 treatment, suggesting that the drug selectively targets MCL cells without affecting healthy cells.
Return to Home
Chemical List
Knowledge you may be interested in